Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin. 2025;9(2):s532. doi:10.25251/skin.10.supp.532